Oh boy, your logic is flawed on so many levels that I just don't know where to begin. First, what does an RCC trial have to do with Sarcoma...not only are they completely different diseases but the two trials had completely different patient populations which makes drawing any conclusion between the two downright silly...apples and oranges, imo. Second, I suggest you check out the everolimus' P2 sarcoma results - everolimus had about a 50% lower PFS when compared to rida's P2 results. The fact that the DMC greenlighted the second interim results indicates that the arms are diverging otherwise the trial would have stopped. The simplest explanation is that a disease stable population is likely to take longer to diverge, again, imo, this is not unexpected. Finally, you've made the claim about Harvey knowing something and "hedging". Any proof or is this just pure conjecture on your part. Since YOU are the one making the claim, its up to YOU to support it.
